Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
48,446,966

-0.41 (-1.43%)

Updated Aug 16, 2024 04:01 PM ET

After-Market: $28.26 -0.04 (-0.14%) 7:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Horizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View

Horizon Pharma plc (HZNP) topped both earnings and sales estimate in second-quarter 2017 and raised its sales guidance for 2017.

    The Zacks Analyst Blog Highlights: Apple, Pfizer, Intel, Chevron and Exxon Mobil

    The Zacks Analyst Blog Highlights: Apple, Pfizer, Intel, Chevron and Exxon Mobil

      Sweta Killa headshot

      Q2 Earnings Fail to Impress Pharma ETF

      The string of earnings beat failed to boost pharma ETFs.

        Swarup Gupta headshot

        Dow 30 Stock Roundup: Apple Impresses, Pfizer Beats on Earnings

        The Dow breached the psychological 22,000 barrier during a week of strong gains.

          Market News For August 04, 2017

          The blue-chip index registered its 33rd record for 2017 to finish above the 22,000 threshold yet again on a day marked by losses for other benchmarks.

            Arpita Dutt headshot

            Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals

            Pfizer's (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.

              Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat

              Momenta Pharmaceuticals Inc (MNTA)'s loss per share came in line with estimates in the second quarter of 2017 while sales beat estimates driven by Glatopa 20mg.

                Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2

                Aerie Pharmaceuticals, Inc.'s (AERI) narrower-than-expected loss in the second quarter was encouraging.

                  Company News For August 02, 2017

                  Companies in the news are: XRX,ADM,RCL,PFE

                    Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings?

                    DENTSPLY Sirona's (XRAY) results are likely to be boosted by surging dental & healthcare consumables space in the yet-to-be-reported second quarter.

                      Q2 Earnings From UA, PFE And ADM

                      Q2 Earnings From UA, PFE And ADM

                        Pfizer (PFE) Surpasses Q2 Earnings Estimates, Misses Sales

                        Pfizer, Inc. (PFE) beat expectations for earnings while missing the same for sales in Q2. It raised the lower end of its 2017 adjusted earnings guidance but kept the revenue expectations intact.

                          Mark Vickery headshot

                          Q2 Earnings Tuesday: Mixed Bag for Most

                          UnderArmour (UAA), Pfizer (PFE), Archer Daniels Midland (ADM), among others, hit the tape this morning.

                            Becton, Dickinson (BDX) Q2 Earnings: What's in the Cards?

                            Becton, Dickinson's (BDX) second-quarter performance faces risks from unfavorable foreign exchange rate.

                              Pfizer (PFE) Tops Q2 Earnings Estimates, Misses Sales

                              Pfizer, Inc. (PFE) beat expectations for earnings while missing the same for sales in Q2. It raised the lower end of its 2017 adjusted earnings guidance but kept the revenue expectations intact.

                                Arpita Dutt headshot

                                Key FDA Events to Watch Out for in Aug 2017

                                Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?

                                  Allergan (AGN) to Report Q2 Earnings: What's in the Cards?

                                  While Allergan plc's (AGN) Q2 sales are likely to be driven by new as well as established products and international growth, earnings will likely be driven by sales growth and cost control.

                                    Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY

                                    The Medical sector has carried on the momentum of its first quarter performance so far this earnings season but lagged the overall market.

                                      What's in the Cards for Immune Design (IMDZ) in Q2 Earnings?

                                      Immune Design Corp (IMDZ) is likely to focus on data from studies on its pipeline candidates- CMB305 and G100 in Q2.

                                        Apple, Pfizer and Yum Brands are part of Zacks Earnings Preview

                                        Apple, Pfizer and Yum Brands are part of Zacks Earnings Preview

                                          Can Cardinal Health (CAH) Pull a Surprise in Q4 Earnings?

                                          Despite an upbeat outlook, cut-throat competition in the niche space and pricing pressure in generics portfolio are likely to mar Cardinal Health's (CAH) results in the fourth quarter.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More

                                            Companies like AstraZeneca (AZN) and Lilly saw their shares fall after the release of second quarter results.

                                              Ryan McQueeney headshot

                                              Upcoming Earnings Reports to Watch: AAPL, PFE, TWX, KHC

                                              We are looking ahead to next week to target the most important upcoming reports. Check out the latest on Apple (AAPL), Pfizer (PFE), Time Warner (TWX), and Kraft Heinz (KHC) ahead of their earnings report dates.

                                                Merck (MRK) Beats on Q2 Earnings and Sales, Keeps 2017 View

                                                Merck & Co., Inc. (MRK) beat estimates for both earnings and sales in Q2 mainly backed by strong sales of PD-1 inhibitor, Keytruda.

                                                  Why Pfizer Inc. (PFE) Might Surprise This Earnings Season

                                                  Pfizer Inc. (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.